http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 13 Aug 2026 07:05:01 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Cognition+Therapeutics+%28CGTX%29/26916289.html <p>H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ: CGTX).</p><p>The analyst commented: "Cognition Therapeutics remains slated to initiate a pivotal program with its lead candidate zervimesine to treat psychosis associated with dementia with Lewy bodies (DLB), which would support a New Drug Application (NDA). The registrational program is expected to begin in mid-2027. Cognition expects the Phase 3 study to enroll people with DLB who experience psychosis symptoms of hallucinations and delusions. Patients receiving stable background treatment with off-label antipsychotic medications shall be eligible. Following screening, participants will be randomized to receive http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Cognition+Therapeutics+%28CGTX%29/26916289.html Thu, 13 Aug 2026 07:05:01 -0400 CGTX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++COGNITION+THERAPEUTICS++++For%3A+Jun+30/26887543.html si-local-file:///var/storage/secattach/20260807/26887543.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++COGNITION+THERAPEUTICS++++For%3A+Jun+30/26887543.html Fri, 07 Aug 2026 07:31:00 -0400 CGTX O.04148427 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++COGNITION+THERAPEUTICS++++For%3A+Jun+30/26887543.html si-local-file:///var/storage/secattach/20260807/26887543.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++COGNITION+THERAPEUTICS++++For%3A+Jun+30/26887543.html Fri, 07 Aug 2026 07:31:00 -0400 CGTX O.04148427 http://www.streetinsider.com/Earnings/Cognition+Therapeutics%2C+Inc.+%28CGTX%29+Tops+Q2+EPS+by+1c/26885838.html <p>Cognition Therapeutics, Inc. (NASDAQ: CGTX) reported Q2 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05).</p><p>For earnings history and earnings-related data on Cognition Therapeutics, Inc. (CGTX) <a href="http://www.streetinsider.com/ec_earnings.php?q=CGTX">click here</a>.</p> http://www.streetinsider.com/Earnings/Cognition+Therapeutics%2C+Inc.+%28CGTX%29+Tops+Q2+EPS+by+1c/26885838.html Thu, 06 Aug 2026 18:02:58 -0400 CGTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Aug+06/26884389.html si-local-file:///var/storage/secattach/20260806/26884389.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Aug+06/26884389.html Thu, 06 Aug 2026 16:19:00 -0400 CGTX O.04148427 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Aug+06/26884389.html si-local-file:///var/storage/secattach/20260806/26884389.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Aug+06/26884389.html Thu, 06 Aug 2026 16:19:00 -0400 CGTX O.04148427 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Reports+Financial+Results+for+the+Second+Quarter+2026+and+Provides+Business+Update/26883954.html <p align="left">PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=39qKHaUIBnd8PfA8zbeU8l7FssGw7KQEh2yJJmZfZ3ZaBj03L1IEU5ljLEL1iEW0vgCa_yYHbeOC4BswbA6XNFw_lGPQXzFiegli6Muv5lY=" rel="nofollow" target="_blank"><strong>Cognition Therapeutics, Inc.</strong></a> (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2026, and provided a business update.</p> <p align="left">“The second quarter marked important progress across both our clinical and corporate priorities,” said Lisa Ricciardi, Cognition’s president and CEO. “Discussions with the Food and Drug Administration (FDA) brought clarity on key aspects of our planned Phase 3 trial for people with dementia with Lewy bodies (DLB) who http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Reports+Financial+Results+for+the+Second+Quarter+2026+and+Provides+Business+Update/26883954.html Thu, 06 Aug 2026 16:15:00 -0400 CGTX http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Reports+Financial+Results+for+the+Second+Quarter+2026+and+Provides+Business+Update/26883954.html <p align="left">PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=39qKHaUIBnd8PfA8zbeU8l7FssGw7KQEh2yJJmZfZ3ZaBj03L1IEU5ljLEL1iEW0vgCa_yYHbeOC4BswbA6XNFw_lGPQXzFiegli6Muv5lY=" rel="nofollow" target="_blank"><strong>Cognition Therapeutics, Inc.</strong></a> (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2026, and provided a business update.</p> <p align="left">“The second quarter marked important progress across both our clinical and corporate priorities,” said Lisa Ricciardi, Cognition’s president and CEO. “Discussions with the Food and Drug Administration (FDA) brought clarity on key aspects of our planned Phase 3 trial for people with dementia with Lewy bodies (DLB) who http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Reports+Financial+Results+for+the+Second+Quarter+2026+and+Provides+Business+Update/26883954.html Thu, 06 Aug 2026 16:15:00 -0400 CGTX http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Press+Releases/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html <p>PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NvOEUyCe2B-9Gddz9FMZLZ4NVfOOhpZReeogcdndoWuZfV8kpgKmZODpb4jlIDNZAJA_DOXcRnEA_At1Qc3cn50KpcKD9J8cZqRCqYnwOPp856NUnPbKpx4cDbNqxCXP" rel="nofollow" target="_blank">Cognition Therapeutics, Inc.</a> (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=NpFDUuC_pZfzH5SZqO7f1i_VvEGQqa7u9vg-n_v_enJqPSdZQoPW0x5TFTJNO-jP0BaRxlxZpH5zB-P-JRxRNUfah8B1Jdm8yIOmzTzY1dq3KRSsubE0Yr4M2gCXTyOZFu8sg6_i6CvojkAVB2S6cSGAmayUu4nZ-bTu6MbIkRF0x1i4slP65gy_lqkUHg5v" rel="nofollow" target="_blank">Lisa Ricciardi</a>, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle &amp; Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company&apos;s ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia http://www.streetinsider.com/Globe+Newswire/Cognition+Therapeutics+Participating+in+Fireside+Chat+at+B.+Riley+Securities%26apos%3B+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26759812.html Mon, 13 Jul 2026 07:30:00 -0400 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.54516537 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Cognition+Therapeutics+%28CGTX%29/26716723.html <p>H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $3.00 price target on Cognition Therapeutics (NASDAQ: CGTX).</p><p>The analyst commented: "Cognition Therapeutics recently reported that it has received written feedback from the FDA following its recent meeting with agency reviewers. The FDA agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome and reached alignment with the company on key aspects of a pivotal trial to support a New Drug Application (NDA). The registrational program is expected to begin in mid-2027. Cognition expects the Phase 3 study to enroll people with DLB who experience psychosis http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Cognition+Therapeutics+%28CGTX%29/26716723.html Wed, 01 Jul 2026 07:05:11 -0400 CGTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Jun+24/26682235.html si-local-file:///var/storage/secattach/20260624/26682235.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Jun+24/26682235.html Wed, 24 Jun 2026 07:39:00 -0400 CGTX O.04148427 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Jun+24/26682235.html si-local-file:///var/storage/secattach/20260624/26682235.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++COGNITION+THERAPEUTICS++++For%3A+Jun+24/26682235.html Wed, 24 Jun 2026 07:39:00 -0400 CGTX O.04148427 http://www.streetinsider.com/FDA/FDA+aligns+with+Cognition+Therapeutics+on+Phase+3+DLB+psychosis+trial/26682196.html <p>Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced it received written feedback from the U.S. Food and Drug Administration following a recent meeting, in which the agency agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome and reached alignment on key aspects of a pivotal trial design to support a New Drug Application for zervimesine (CT1812).</p> <p>The registrational program is expected to begin in mid-2027. The planned Phase 3 study will enroll patients with DLB who experience hallucinations and delusions, including those on stable background treatment with off-label antipsychotic medications. Participants will be randomized to receive either http://www.streetinsider.com/FDA/FDA+aligns+with+Cognition+Therapeutics+on+Phase+3+DLB+psychosis+trial/26682196.html Wed, 24 Jun 2026 07:30:32 -0400 A.06822034 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.20026344 O.54516537 http://www.streetinsider.com/FDA/FDA+aligns+with+Cognition+Therapeutics+on+Phase+3+DLB+psychosis+trial/26682196.html <p>Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced it received written feedback from the U.S. Food and Drug Administration following a recent meeting, in which the agency agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome and reached alignment on key aspects of a pivotal trial design to support a New Drug Application for zervimesine (CT1812).</p> <p>The registrational program is expected to begin in mid-2027. The planned Phase 3 study will enroll patients with DLB who experience hallucinations and delusions, including those on stable background treatment with off-label antipsychotic medications. Participants will be randomized to receive either http://www.streetinsider.com/FDA/FDA+aligns+with+Cognition+Therapeutics+on+Phase+3+DLB+psychosis+trial/26682196.html Wed, 24 Jun 2026 07:30:32 -0400 A.06822034 A.19655944 A.50216777 CGTX O.03307993 O.04148427 O.20026344 O.54516537